v3.25.2
Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Sep. 30, 2024
Cash flows from operating activities          
Net increase (decrease) in net assets resulting from operations $ 90,058 $ 9,252 $ 280,356 $ 178,586  
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by (used in) operating activities:          
Amortization of deferred debt issuance costs 2,413 2,214 7,537 6,869  
Accretion of discounts and amortization of premiums on investments     (5,524) 1,267  
Accretion of discounts and amortization of premiums on issued debt securities     2,507 (10,996)  
Net realized (gain) loss on investments     41,844 49,505  
Net realized (gain) loss on foreign currency transactions 400 6,206 4,279 1,560  
Net realized (gain) loss on forward currency contracts 0 (624) (7,203) (624)  
Net realized (gain) loss on extinguishment of debt 0 0 48 0  
Net change in unrealized (appreciation) depreciation on investments     (25,877) 35,609  
Net change in unrealized (appreciation) depreciation on translation of assets and liabilities in foreign currencies (23,857) (3,709) (12,311) 260  
Proceeds from (fundings of) revolving loans, net     (7,592) (4,658)  
Fundings of investments     (1,781,515) (554,521)  
Proceeds from principal payments and sales of portfolio investments     1,146,022 867,233  
Proceeds from settlements of forward currency contracts     10,264 1,123  
Payment-in-kind interest capitalized (12,518) (11,245) (40,439) (36,551)  
Non-cash dividends capitalized     (23,091) (13,890)  
Proceeds from non-cash dividends     4,288 47  
Cash acquired in GBDC 3 Merger     0 53,885  
Changes in operating assets and liabilities:          
Cash collateral held at broker for derivatives     (8,410) (11,670)  
Interest receivable     3,253 8,374  
Receivable for investments     (1,263) 0  
Other assets     261 (20,191)  
Interest payable     5,745 23,750  
Management and income incentive fees payable     6,994 (29,853)  
Accrued trustee fees     343 155  
Accounts payable and other liabilities [1]     (557) (2,730)  
Net cash provided by (used in) operating activities     (379,713) 543,942  
Cash flows from financing activities          
Borrowings on debt     3,517,912 1,966,609  
Repayments of debt     (3,008,603) (1,971,861)  
Capitalized debt issuance costs     (9,029) (13,488)  
Net proceeds from issuance of common stock (Note 11)     37,434 0  
Purchases of common stock (Note 11)     (35,466) 0  
Distributions paid     (280,970) (199,173)  
Purchases of common stock for dividend reinvestment plan     (20,554) 0  
Net cash provided by (used in) financing activities     200,724 (217,913)  
Net change in cash and cash equivalents, foreign currencies, restricted cash and cash equivalents and restricted foreign currencies     (178,989) 326,029  
Effect of foreign currency exchange rates     (1,790) (1,521)  
Cash and cash equivalents, foreign currencies, restricted cash and cash equivalents and restricted foreign currencies, beginning of period     359,552 [2] 140,206 $ 140,206
Cash and cash equivalents, foreign currencies, restricted cash and cash equivalents and restricted foreign currencies, end of period 178,773 [2] 464,714 178,773 [2] 464,714 359,552 [2]
Supplemental disclosure of cash flow information:          
Cash paid during the period for interest [3]     199,922 110,623  
Distributions declared for the period 335,228 243,455 335,228 243,455  
Noncash assets acquired:          
Investments, at cost [4]     0 2,623,381  
Interest receivable [4]     0 32,204  
Unrealized appreciation on forward currency contracts [4]     0 6,334  
Receivable for investments sold [4]     0 8,922  
Other assets [4]     0 154  
Total noncash assets purchased [4]     0 2,670,995  
Liabilities assumed:          
Debt [4]     0 1,211,174  
Interest payable [4]     0 12,671  
Distributions payable [4]     0 9,516  
Management and income incentive fees payable [4]     0 8,921  
Accrued trustee fees [4]     0 8  
Accounts payable and other liabilities [4]     0 4,040  
Total liabilities assumed [4]     0 1,246,330  
Issuance of common stock [4]     0 1,526,351  
Merger costs capitalized into purchase price [4]     0 3,867  
Reconciliation of cash and cash equivalents, foreign currencies and restricted cash and cash equivalents and restricted foreign currencies          
Cash and cash equivalents 91,855   91,855   123,120
Foreign currencies (cost of $7,823 and $7,973, respectively) 7,901   7,901   8,044
Restricted cash and cash equivalents 79,017   79,017   227,152
Restricted foreign currencies (cost of $0 and $1,219, respectively) 0   0   1,236
Total cash and cash equivalents, foreign currencies, restricted cash and cash equivalents and restricted foreign currencies shown in the Consolidated Statements of Cash Flows 178,773 [2] 464,714 178,773 [2] 464,714 $ 359,552 [2]
Interest Rate Swap          
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by (used in) operating activities:          
Net change in unrealized (appreciation) depreciation on derivatives     4,541 2,992  
Foreign exchange          
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by (used in) operating activities:          
Net realized (gain) loss on forward currency contracts 0 (624) (7,203) (624)  
Net change in unrealized (appreciation) depreciation on derivatives $ 22,219 $ (2,972) $ 15,787 $ (1,589)  
[1] Includes payment of $9,516 distribution payable of GBDC 3 shareholders that was assumed in the GBDC 3 Merger (defined in Note 1).
[2] See Note 2 for a description of cash and cash equivalents, foreign currencies, restricted cash and cash equivalents and restricted foreign currencies.
[3] Includes cash paid or received for contractual interest rate swaps, which may have different contractual settlement dates among the (i) fixed interest leg, (ii) floating interest leg
and (iii) the debt instrument.
[4] Refer to Note 1 for more information related to our acquisition of GBDC 3.